Cytomx Therapeutics Stock Performance
| CTMX Stock | USD 5.74 0.05 0.88% |
On a scale of 0 to 100, CytomX Therapeutics holds a performance score of 10. The firm shows a Beta (market volatility) of -1.11, which signifies a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning CytomX Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, CytomX Therapeutics is expected to outperform it slightly. Please check CytomX Therapeutics' potential upside, as well as the relationship between the accumulation distribution and price action indicator , to make a quick decision on whether CytomX Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in CytomX Therapeutics are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. In spite of fairly conflicting primary indicators, CytomX Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.87) | Five Day Return 3.45 | Year To Date Return 33.88 | Ten Year Return (64.12) | All Time Return (55.89) |
1 | Analysts Just Shaved Their CytomX Therapeutics, Inc. Forecasts Dramatically | 11/13/2025 |
2 | Will CytomX Therapeutics Inc. stock beat EPS estimates - Market Performance Report Reliable Breakout Forecasts - Newser | 12/05/2025 |
3 | Can CytomX Therapeutics Stock Hold Up When Markets Turn - Trefis | 12/10/2025 |
4 | CytomX Therapeutics earnings growth rate lags the 256 percent return delivered to shareholders | 12/19/2025 |
5 | Acquisition by Chu Yu-waye of 43750 shares of CytomX Therapeutics subject to Rule 16b-3 | 12/26/2025 |
6 | CytomX Therapeutics Hits New 1-Year High - Heres Why - MarketBeat | 01/02/2026 |
7 | CytomX Therapeutics Announces Business Update and Company Milestones for 2026 | 01/08/2026 |
8 | CytomX Therapeutics Receives Target Price Upgrade from Pi - GuruFocus | 01/20/2026 |
9 | Is CytomX Therapeutics, Inc.s Stocks Recent Performance Being Led By Its Attractive Financial Prospects | 01/23/2026 |
10 | Acquisition by Jones Elaine V of 38000 shares of CytomX Therapeutics at 1.96 subject to Rule 16b-3 | 01/27/2026 |
11 | What CytomX Therapeutics, Inc.s 35 percent Share Price Gain Is Not Telling You | 01/28/2026 |
| Begin Period Cash Flow | 18.1 M | |
| Total Cashflows From Investing Activities | 99.7 M |
CytomX Therapeutics Relative Risk vs. Return Landscape
If you would invest 393.00 in CytomX Therapeutics on November 3, 2025 and sell it today you would earn a total of 181.00 from holding CytomX Therapeutics or generate 46.06% return on investment over 90 days. CytomX Therapeutics is currently generating 0.767% in daily expected returns and assumes 5.7312% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than CytomX, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CytomX Therapeutics Target Price Odds to finish over Current Price
The tendency of CytomX Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.74 | 90 days | 5.74 | near 1 |
Based on a normal probability distribution, the odds of CytomX Therapeutics to move above the current price in 90 days from now is near 1 (This CytomX Therapeutics probability density function shows the probability of CytomX Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days CytomX Therapeutics has a beta of -1.11 suggesting Moreover CytomX Therapeutics has an alpha of 1.0448, implying that it can generate a 1.04 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). CytomX Therapeutics Price Density |
| Price |
Predictive Modules for CytomX Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as CytomX Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.CytomX Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. CytomX Therapeutics is not an exception. The market had few large corrections towards the CytomX Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold CytomX Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of CytomX Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.04 | |
β | Beta against Dow Jones | -1.11 | |
σ | Overall volatility | 0.62 | |
Ir | Information ratio | 0.17 |
CytomX Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of CytomX Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for CytomX Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| CytomX Therapeutics is way too risky over 90 days horizon | |
| CytomX Therapeutics appears to be risky and price may revert if volatility continues | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (86.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94. | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: What CytomX Therapeutics, Inc.s 35 percent Share Price Gain Is Not Telling You |
CytomX Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of CytomX Stock often depends not only on the future outlook of the current and potential CytomX Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. CytomX Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 84.7 M | |
| Cash And Short Term Investments | 100.6 M |
CytomX Therapeutics Fundamentals Growth
CytomX Stock prices reflect investors' perceptions of the future prospects and financial health of CytomX Therapeutics, and CytomX Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CytomX Stock performance.
| Return On Equity | 0.67 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.25 % | ||||
| Operating Margin | (2.64) % | ||||
| Current Valuation | 834.53 M | ||||
| Shares Outstanding | 169.44 M | ||||
| Price To Earning | (11.41) X | ||||
| Price To Book | 9.06 X | ||||
| Price To Sales | 8.17 X | ||||
| Revenue | 138.1 M | ||||
| Gross Profit | 113.63 M | ||||
| EBITDA | 26.76 M | ||||
| Net Income | 31.87 M | ||||
| Cash And Equivalents | 194.29 M | ||||
| Cash Per Share | 2.94 X | ||||
| Total Debt | 9.38 M | ||||
| Debt To Equity | 0.67 % | ||||
| Current Ratio | 2.05 X | ||||
| Book Value Per Share | 0.65 X | ||||
| Cash Flow From Operations | (86.23 M) | ||||
| Earnings Per Share | 0.30 X | ||||
| Market Capitalization | 928.51 M | ||||
| Total Asset | 120.53 M | ||||
| Retained Earnings | (691.58 M) | ||||
| Working Capital | 21.53 M | ||||
| Current Asset | 189.75 M | ||||
| Current Liabilities | 15.74 M | ||||
About CytomX Therapeutics Performance
Evaluating CytomX Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if CytomX Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CytomX Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.24 | 0.25 | |
| Return On Capital Employed | 0.65 | 0.68 | |
| Return On Assets | 0.24 | 0.25 | |
| Return On Equity | (62.90) | (59.75) |
Things to note about CytomX Therapeutics performance evaluation
Checking the ongoing alerts about CytomX Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CytomX Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CytomX Therapeutics is way too risky over 90 days horizon | |
| CytomX Therapeutics appears to be risky and price may revert if volatility continues | |
| CytomX Therapeutics currently holds about 194.29 M in cash with (86.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.94. | |
| Over 89.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: What CytomX Therapeutics, Inc.s 35 percent Share Price Gain Is Not Telling You |
- Analyzing CytomX Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CytomX Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CytomX Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CytomX Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CytomX Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CytomX Therapeutics' stock. These opinions can provide insight into CytomX Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for CytomX Stock Analysis
When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.